NCT05116189 2026-03-09KEYNOTE-B96Merck Sharp & Dohme LLCPhase 3 Active not recruiting643 enrolled 17 charts 1 FDA
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT00565851 2025-12-30Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting1,052 enrolled 27 charts
NCT03740165 2025-10-22KEYLYNK-001Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,367 enrolled 29 charts
NCT04723875 2024-11-01Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN GuidelineHuazhong University of Science and TechnologyPhase 3 Active not recruiting306 enrolled